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Abstract
A combined genome-wide association and linkage study was used to identify loci causing 
variation in CF lung disease severity. A significant association (P=3. 34 × 10-8) near EHF and 
APIP (chr11p13) was identified in F508del homozygotes (n=1,978). The association replicated in 
F508del homozygotes (P=0.006) from a separate family-based study (n=557), with P=1.49 × 10-9 
for the three-study joint meta-analysis. Linkage analysis of 486 sibling pairs from the family-
based study identified a significant QTL on chromosome 20q13.2 (LOD=5.03). Our findings 
provide insight into the causes of variation in lung disease severity in CF and suggest new 
therapeutic targets for this life-limiting disorder.
Lung disease is the major source of morbidity and mortality in cystic fibrosis (CF), a 
recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene. Allelic variation in CFTR does not explain the wide variation in 
severity of lung disease1 however studies of twins and siblings demonstrate substantial 
heritability underlying differences in lung function measures in CF patients (h2 > 0.5)2. 
Candidate gene studies have produced conflicting results, with only a few large scale 
replications accounting for a small proportion of heritable variation in CF lung function3,4. 
Identification of other genetic modifiers could identify potential mechanisms for variation in 
lung function in CF, as well as for common diseases such as chronic obstructive pulmonary 
disease (COPD), and suggest new targets for intervention.
Whole-genome methods provide an attractive approach to identify modifier loci of 
Mendelian disorders. However CF presents numerous challenges, such as: (1) collecting 
multiple years of lung function measures to accurately classify lung disease severity; (2) 
selecting the appropriate study design to identify common and rare variants; (3) accruing 
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sufficient sample sizes, and (4) accounting for potential interaction between CFTR and 
modifier loci. To overcome these challenges, we formed a North American CF Gene 
Modifier Consortium to identify modifiers of lung disease severity and other phenotypes. 
For lung disease in CF, the forced expiratory volume in 1 second (FEV1) is the most 
clinically useful measure of lung disease severity and is a well-established predictor of 
survival5,6. However, comparison of FEV1 measures across a broad age range of CF patients 
is confounded by decline with age and mortality attrition. To account for these confounders, 
the Consortium developed a quantitative lung disease phenotype based on multiple measures 
of FEV1 over 3 years7 that displays robust genetic influence (h2 = 0.51)8.
The Consortium is composed of three samples of CF patients recruited using different study 
designs. The Genetic Modifier Study (GMS) consists of unrelated patients homozygous for 
the common CF allele F508del (HGVS nomenclature: p.Phe508del), recruited from 
extremes of lung function9. The Canadian Consortium for Genetic Studies (CGS) enrolled 
unrelated patients having pancreatic insufficiency from a population-based sample10. The 
CF Twin and Sibling Study (TSS) recruited families where two or more surviving children 
have CF2. The GMS and CGS were designed for association analysis, while the TSS was 
designed for both linkage and association, providing an opportunity to detect rarer variants 
or poorly tagged loci.
As many current Genome Wide Association Studies (GWASs) employ sample sizes that are 
several-fold larger than available for the CF population, we sought to maximize power by 
(1) testing association using combined data from GMS and CGS, followed by replication 
using the association evidence from TSS, and (2) testing linkage using the TSS, followed by 
SNP association testing in linked regions in the unrelated patients in GMS and CGS. We 
also restricted analysis to patients bearing two severe loss-of-function CFTR alleles and a 
subset of these patients that had identical CFTR genotypes (homozygosity for F508del).
RESULTS
Genome-wide association analysis of lung disease severity in CF
A total of 3,467 CF patients are represented in three study designs (Table 1, Supplementary 
Note). Patients in the GMS and 60% of the patients in the CGS and TSS are F508del 
homozygotes (F508del/F508del), while the remainder has other severe exocrine pancreatic 
CFTR genotypes2,9,10. The three samples showed consistent distributions of the lung disease 
phenotype, with the mid-range under-represented in GMS due to the extremes-of-phenotype 
design (Figure 1). Patients were contemporaneously genotyped using the Illumina 610-Quad 
array® in a single facility with stringent quality control (Online Methods). Association scans 
for the GMS and CGS used an additive model adjusted for sex and principal components as 
described11. Results were combined using a directional meta-analysis approach for (1) GMS 
and CGS, n=2,494 and (2) GMS and CGS F508del/F508del, n=1,978 (power analysis 
shown in Supplementary Figure 1).
The combined GMS and CGS analysis identified seven regions with suggestive association 
(P ≤ 1/570,725 = 1.75 × 10-6) (Figure 2 and Table 2). Restricting analysis to F508del/
F508del patients, the EHF-APIP region on 11p13 achieved genome-wide significance at 
Wright et al. Page 3













rs12793173 (P=3.34 × 10-8, explaining 1.0% of the phenotype variation in GMS, 2.2% in 
CGS F508del/F508del). We verified the significance by permutation analysis and by 
developing an alternative conditional likelihood approach which acknowledged the GMS 
extremes of phenotype (Online Methods, Supplementary Figure 2). With the inclusion of 
CF-relevant covariates (sex, BMI and previously associated genes), association for 
rs12793173 was even stronger (P= 9.42 × 10-9 for GMS and CGS F508del/F508del; 
Supplementary Table 1). Two purported modifiers of CF lung disease, TGFB1 and IFRD1, 
did not achieve genome-wide significance. TGFB1 did, however, achieve P-values in the 
range of 10-3 to 10-4 in the GMS sample, depending on additional covariates 
(Supplementary Table 1).
The SNPs in the significant region and the six suggestive regions in GMS and CGS were 
evaluated for association in TSS using Merlin12, while accounting for family structure. To 
be consistent with the GMS and CGS allelic effect, each replication test was one-sided, with 
the TSS sample (all or F508del/F508del patients) for each suggestive SNP chosen to be 
consistent with the GMS and CGS sample set providing maximum significance. Covariates 
for sex and four principal components11 were included for TSS. The SNP attaining genome-
wide significance in GMS and CGS (rs12793173, F508del/F508del) demonstrated 
significant association in the TSS F508del/F508del sample (P=0.006; Bonferroni corrected 
P = 0.041 for the seven replication tests; Table 2). Two of the suggestive SNPs provided 
modest evidence in TSS: rs9268905 near HLA-DRA (P=0.032) and rs1403543 near AGTR2 
(P=0.053), with neither significant after correcting for the seven replication tests.
We next performed a joint analysis, shown to be more powerful than testing followed by 
replication13, using a weighted meta-analysis procedure (Online Methods). Using all 
patients, rs12793173 attained genome-wide significance (P=1.12 × 10-8). For this patient 
set, rs568529, a SNP in high LD (r2 > 0.9) with rs12793173, achieved slightly greater 
significance (P=9.75 × 10-9). As in the earlier analysis, restricting to F508del/F508del 
patients increased the significance of EHF-APIP (P=1.49 × 10-9 for rs12793173 (Table 2), 
P=8.28 × 10-10 for rs568529). In the HLA class II region, a SNP (rs2395185, ~1kb from the 
suggestive SNP rs9268905 identified from GMS and CGS) approached genome-wide 
significance using all patients (P=9.02 × 10-8; Supplementary Figure 3). SNPs in AGTR2 
remained suggestive for all patients (rs5952206, P=1.25 × 10-7) and for F508del/F508del 
patients (rs7060450, P=3.67 × 10-7).
Figure 3 shows the GMS and CGS results for an 800kb interval including EHF-APIP. The 
minimum P-value appears in an intergenic region 3’ to both EHF and APIP. A second peak 
at rs286873 (P=5.62 × 10-7) near EHF exhibited low linkage disequilibrium (r2 < 0.2) with 
the primary SNP (Figure 3). After conditioning on the primary finding, rs286873 had 
regional statistical significance (rs12793173; corrected P=0.0029), suggesting additional 
regional genetic variants (Supplementary Figure 4). We repeated the testing after MACH 
imputation14. The imputed SNPs in the region identified the same EHF/APIP interval, with 
minimum P=1.45 × 10-8, at rs535719, at a position 19kb closer to APIP than rs12793173. 
None of the imputed SNPs produced substantially improved association evidence 
(Supplementary Figure 5). Neither total copy number nor allele-specific copy number 
(Online Methods) models met genome-wide significance (illustrative Manhattan plot in 
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Supplementary Figure 6). Finally, after sequencing the exonic regions of EHF and APIP in 
48 patients with mild pulmonary disease and 48 patients with severe pulmonary disease 
from the GMS, no additional genetic variation was found that offered insight into putative 
modifying roles (data not shown).
Linkage of lung disease severity in CF to chromosome 20q13.2
Linkage analysis revealed a genome-wide significant multipoint LOD score of 5.03 at 
rs4811626, located at 53.81 Mb (~85cM) on chromosome 20q13.2 (nominal P=7.9 × 10-7 ; 
genome-wide15 P=2.3 × 10-3; Figure 4). Another, but more modest linkage signal was on 
chromosome 1p22.21, with multipoint LOD score of 2.48 for rs941031at 91.07 Mb (119 
cM). Inclusion of BMI-Z, an important covariate of CF lung function (Supplementary Table 
1), increased the LOD score for the linkage peak on 20q13.2 to 5.72 (genome-wide P=5.05 
× 10-4 at rs4811645 which is 0.07cM (0.13Mb) from rs4811626; Figure 5) while linkage on 
chromosome 1p22.21 decreased to LOD 1.67. Thus, anthropometric measures are not major 
contributors to the linkage on 20q13.2 but may be playing a role on 1p22.21. We estimated 
that the QTL at 20q13.2 is approaching 50% of the variation in lung function in the CF 
sibling pairs (Supplementary Figure 7); however, this estimate is highly likely to be biased 
upward due to winner’s curse16.
A region of 1.31 Mb on 20q13.2, demarcated by 1 LOD unit below the maximum (when 
BMI-Z was used as a covariate), was analyzed for association in the combined GMS and 
CGS samples. A 16kb cluster of SNPs in high LD (rs6092179, rs6024437, rs8125625, 
rs6024454 and rs6024460; r2 > 0.8) located ~200kb from CBLN4 generated the lowest P-
values in the combined GMS and CGS F508del/F508del samples (Figure 5). The SNP with 
the lowest P-value (rs6024460; P=1.34 × 10-4) reached regional significance (corrected P = 
0.041). Association in the TSS identified a SNP (rs6069437) with marginal association 
(uncorrected P = 0.014) that displays weak LD with the GMS and CGS cluster of SNPs. 
Imputation did not identify any SNPs exhibiting a lower P value for association than 
rs6024460 (Supplementary Figure 8).
A combined false discovery rate approach corroborates genome-wide significance of loci 
on chromosomes 11 and 20
To evaluate association and linkage in a single framework, linkage information was used to 
reprioritize genome-wide association using extensions of the false discovery rate (FDR)17 
via the stratified FDR (SFDR)18 and weighted FDR (WFDR)19. We (1) obtained linkage-
weighted q-values representing the combined evidence at each SNP, and (2) re-ranked 
GWAS results by linkage-weighted q-values (see Online Methods). Results are presented 
from the WFDR; results were confirmed using the SFDR (data not shown). SNPs with q-
values less than 0.05 were declared to be genome-wide significant (Table 3). SNPs in the 
EHF-APIP region on chromosome 11 are highly significant (low q-values), because of the 
strong association (Table 3). After accounting for linkage, the q-values for SNPs under the 
linkage peak on chromosome 20 are considerably decreased. The results presented in Table 
3 illustrate that the linked SNPs on chromosome 20 are now top ranked genome-wide, while 
they were ranked 154th or lower, prior to incorporating the linkage information. The top-
ranked SNP by the WFDR analysis was rs6092179 at 53.81 Mb on chr 20 (WFDR q-
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value=0.015, Table 3). SNP rs6092179 is within an LD block containing 4 other SNPs 
(rs6024437, rs8125625, rs6024454 and rs6024460), all demonstrating association with CF 
lung function and q-value <0.05. A rank-based q-value Manhattan plot demonstrates that 
chromosome 11 and chromosome 20 both attain genome-wide significance (Supplementary 
Figure 9).
DISCUSSION
We identified two new loci containing genetic variants contributing to variation in lung 
function in CF patients. The success of this project reflected: 1) coordinated analysis of three 
independent samples of the CF population (representing ~15% of all patients in North 
America) where each study subject was characterized by the same quantitative measure of 
lung function; 2) simultaneous genotyping of samples using a single platform which allowed 
for data cleaning using relatedness assessments and removal of poor quality genotypes based 
on parent to child transmission predictions; 3) analyzing for loci with small effect sizes 
using association, and loci of major effect (even in the presence of substantial allelic 
heterogeneity) using linkage. Moreover, we garnered increased power from an extreme of 
phenotype sample, while a population-based sample allowed for the development of a 
phenotype with external validity.
The association at chr11p13 is in an intergenic region 3’ to APIP and EHF with regulatory 
features including: i) significant conservation across species, ii) open chromatin (DNAase 
hypersensitivity and FAIRE-Seq), and iii) DNAase hypersensitive patterns suggesting cell-
type-specificity (http://genome.ucsc.edu). The UCLA Gene Expression Tool (UGET, http://
genome.ucla.edu/~jdong/GeneCorr.html)20,21 indicates correlation of expression of nearby 
genes, including strong correlation of EHF to ELF5, both epithelial-specific transcription 
factors; APIP to PDHX, which have the same promoter region; and EHF to APIP. APIP 
(Apaf-1-interacting protein) is known to inhibit apoptosis by binding to APAF-1, an 
important activator of caspase-922, 23 and by APAF-1 independent activation of AKT and 
ERK1/224. EHF is a member of epithelial-specific-Ets transcription factors that share a 
conserved Ets domain25-27. EHF can be induced in bronchial epithelial cells, smooth muscle 
cells and fibroblasts28,29, leading to transcriptional repression of a subset of ETS/AP-1-
responsive genes activated by MAP-kinase pathways26,28, and in airway it may serve as an 
important regulator of differentiation under conditions of stress and inflammation26,27. Both 
genes show evidence of robust expression in lung and trachea, with APIP showing 
ubiquitous expression across tissues and EHF showing highest expression in trachea (http://
www.ncbi.nlm.nih.gov/UniGene and http://www.ncbi.nlm.nig.gov/geo)30. Interestingly, cis-
eQTL signatures for APIP are reported for lymphocytes and monocytes (eqtl.uchicago.edu). 
Comparing the eQTLs to the direction of phenotype-genotype association suggests that 
increased expression of APIP may be associated with decreased lung function, implying that 
inhibition of apoptosis worsens CF lung disease. This hypothesis is consistent with the 
emerging concepts that delayed neutrophil clearance, due to reduced apoptosis in 
neutrophils in the airways of CF patients, could lead to a hyperinflammatory state and more 
severe lung disease 31,32 and that inhibition of apoptosis contributes to goblet cell 
metaplasia, a central feature in CF airway pathophysiology33.
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All 5 genes within the 1 LOD support interval in the chromosome 20 linkage region (Figure 
5) are expressed in either fetal or adult lung or in bronchial epithelial cells (http://
genome.ucsc.edu/). The 16kb cluster of SNPs associated with lung function in the GMS and 
CGS samples is located ~200kb to 500 kb centromeric to the five genes. None of the SNPs 
lies within a segment of open chromatin identified in the 16kb region in Normal Human 
Bronchial Epithelia cells (http://genome.ucsc.edu). Neither eQTL in lymphocytes 
(eqtl.uchicago.edu), miRNA (http://www.mirbase.org) nor DNaseI hypersensitive sites in 
Small Airway Epithelial cells map to the 16kb region. However, this does not exclude the 
possibility that the associated region regulates expression of any of the five genes or more 
distant genes. Among the five genes, MC3R has been implicated in weight maintenance and 
regulation of energy balance in animals and humans34-36. Variation in resting energy 
expenditure has been correlated with lung function measurements, lung tissue damage and 
lung disease exacerbation in CF patients 37,38. MC3R has also been implicated as a 
modulator of neutrophil accumulation in a murine model of lung inflammation39, a key 
feature of CF lung disease, as noted above. Other genes of interest within the linkage peak 
encode Crk-associated substrate scaffolding (CASS) 4 (CASS4/HEPL), a relative of proteins 
implicated in cell attachment, migration establishing polarity, invasion and phagocytosis of 
bacterial pathogens40 and Aurora kinase A (AURKA) which been shown to interact with 
Hef1/NEDD9, a member of the CASS family that mediates cytokinesis in late mitosis and 
facilitates disassembly of primary cilia41.
Twin studies in adults demonstrate that FEV1 is under strong genetic influence42,43, and at 
least three loci (GSTCD, TNS1 and HTR4) have been reproducibly associated with this 
measure44-46. Multiple replicated loci have also been associated with variation in the 
FEV1/FVC ratio45,46 and at least two of these loci (HHIP and FAM13) show reproducible 
association with COPD44,47,48. While the lung phenotype used here was based on FEV1, 
none of the above loci coincides with the regions identified in this study and neither of the 
loci identified here occur within the top 2000 associations for FEV1 or FEV1/FVC45,46.
Common variation in the EHF/APIP region is estimated to alter the lung function measure 
in the GMS and CGS F508del/F508del patients by ~0.2 units of the quantitative lung 
disease phenotype per allele (Table 2). Translated into more familiar clinical terms, the 0.2 
unit difference is approximately equivalent to a mean difference in FEV1 percent predicted 
of 5.1 ± 1.9, corresponding to a mean difference in FEV1 of 254 ± 86mL in patients over 18 
years of age (Online Methods). The QTL on chromosome 20 may account for a sizeable 
fraction of lung function variation in CF. Using simulations described by Blangero and 
colleagues16, we estimate that this locus accounts for a maximum of 46% and a minimum of 
4% of the variance in the CF siblings (Online Methods).
In summary, our association and linkage approach provided complementary findings with 
the identification of two significant loci harboring genes of biologic relevance for CF. Of 
particular note for modifier searches in other monogenic diseases is the potential importance 
of minimizing variation in the causative gene. When we confined association analysis to 
patients with identical CFTR genotypes (i.e. F508del/F508del), one of the 7 suggestive loci 
achieved genome-wide significance, despite the reduction in sample size due to the 
exclusion of 38% of subjects in the CGS sample with other CFTR genotypes. The remaining 
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suggestive loci contain biologically intriguing candidate modifiers that will be evaluated in 
future studies. Finally, the identification of genetic loci that modify lung function in CF, 
should provide new insight leading to the development of novel therapies for this 
devastating condition.
ONLINE METHODS
Genotyping and quality control
DNA from whole blood or transformed lymphocytes was hybridized to the Illumina 610-
Quad ® platform at Genome Quebec (McGill University and Genome Quebec Innovation 
Centre,) using the 96-well plates with CEPH and one replicate control per plate. Illumina 
BeadStudio® was used to call genotype, and identity confirmed by Sequenom® 
fingerprinting. SNPs were removed if they were monomorphic, missing > 10% calls or with 
>1% Mendelian error in TSS trios. Finally, 570,725 autosomal and X-chromosome SNPs 
were selected, as well as 158 chromosome Y SNPs and 138 mitochondrial SNPs. Duplicate 
discordance was 0.004% in GMS, and similar for the other studies.
Sample exclusions included: initial call rate below 98%, unexpected close relatives or 
duplicate enrollments, unresolved sex mismatches, aneuploidy or outlying heterozygosity (> 
5 standard deviations from the mean of 31.6%). Overlapping from 542 Illumina GoldenGate 
® SNPs in GMS revealed platform discordance of 0.07%. Families with >5% Mendelian 
errors were excluded. Twenty-eight patient samples were excluded (GMS6; CGS 17, TSS 5) 
due to genotyping failure or artifacts, two GMS samples excluded due to outlying ancestry 
(by PC analysis), and eight GMS samples excluded for > second degree relation with other 
samples. Reported findings were verified using Illumina GenomeStudio V1.0.2® module 
V1.0.10 and manually-assisted calling.
Association testing
Regressions for the lung phenotype were performed separately for GMS, all CGS, and CGS 
F508del/F508del using an additive model in PLINK v. 1.07 49, adjusted for sex and 
genotype principal components (PCs)11. Using the PLINK z-statistics for GMS and CGS, 
the standard meta-analysis z-statistic50 was z = wGMSzGMS + wCGSzCGS, with weights 
inversely proportional to standard errors, and common reference alleles for directional 
consistency. “Suggestive” association used the approximate threshold 1/(number of 
SNPs)=1/570,725=1.75 × 10-6, and significant association the Bonferroni threshold P < 
0.05/570,725 = 8.76 × 10-8. For males, X-chromosome genotypes followed PLINK defaults 
(0 or 1 minor alleles; alternative coding resulted in no qualitative changes).
Permutations of genotypes relative to phenotypes and covariates (1,000) were used to refine 
the thresholds. From this pool of permutations, 10,000 permuted meta-analyses were 
computed. The obtained significance thresholds for a genome-wide error 0.05 were P = 1.07 
× 10-7 (GMS and CGS) and P = 1.05 × 10-7 (GMS and CGS F508del/F508del). 
Consequently, P< 5 × 10-8 achieves false positive error control at genome-wide α<0.05, 
even correcting for two separate GWAS analyses. Regional multiple-comparisons correction 
(after highlighting a region) used the Bonferroni correction for the regional SNPs.
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TSS association analysis was performed in 973 CF siblings and for the 557-patient F508del/
F508del subset using the Merlin variance-components additive model framework12, 
corrected for linkage, family structure, sex, and 4 PCs. Missing genotypes (0.125%) were 
inferred to increase power51. Joint analyses of GMS, CGS and TSS used the meta-analysis 
approach described above.
A combined conditional likelihood approach
We devised a novel approach using the assumption that CGS represents a random 
population sample, whereas GMS was conditional on the observed phenotypes. Letting g be 
the number of SNP minor alleles, the phenotypes y were pre-adjusted for sex and the study-
specific PCs. We assumed an additive model y = β0 + β1g + ε, ε ~ N (0, σ2). The full 
likelihood conditioned on GMS sampling was 
where . Finally, we computed 
the SNP-specific statistic 2 × (log-likelihood ratio), with β1 = 0 as the null and compared to 
2 . The approach assumes the effect sizes are the same in GMS and CGS, which is true 
under the null.
Power Analyses
Power analyses for the combination of GMS and CGS assumed an additive genetic model, 
with effect β1 on the average phenotype for each minor allele. The results for GMS and CGS 
F508del/F508del are in Supplementary Figure 1. For each simulation the weighted meta-
analysis P-values were compared to 5 × 10-8.
Genotype imputation
MACH (autosomes, http://www.sph.umich.edu/csg/abecasis/mach/) and IMPUTE 
(chromosome X, http://mathgen.stats.ox.ac.uk/impute/impute.html) imputation was 
conducted for 1162 GMS patients, 1,254 self-reported CGS “Caucasian” patients and 60 
CEU reference samples from HapMap I/II. Some of these individuals were later used for 
TSS, and association analyses considered only unique subsets in GMS and CGS, 
respectively (Table 1). Imputation yielded data for ~2,544,000 autosomal and ~65,000 
chromosome X SNPs.
Copy-number analysis
Copy number variants (CNVs) were detected using pennCNV (2008Nov19 version)52 and 
genoCNV (version 1.08)53 using default parameters in 1103 GMS and 1301 CGS samples. 
CNVs with fewer than 5 probes or showing <1% variation were used, resulting in 
3,008/4,868 probes from genoCNV/pennCNV in GMS and 3015/4663 probes for 
genoCNV /pennCNV in CGS. Genotype PCs were used to control stratification.
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19,566 SNPs were selected from the Illumina platform with minor allele frequency >0.4 and 
r2 <0.01 between adjacent SNPs, using Merlin54. HapMap II recombination data were used 
to integrate genetic and physical map positions. Average inter-marker distance was 0.18 cM, 
or 0.13 Mbp. Physical positions not appearing in HapMap were estimated assuming uniform 
recombination between known adjacent SNPs. The average marker information content was 
~0.9 (multipoint) and ~0.31 (two-point).
Linkage Analysis
Variance components were estimated in SOLAR (Sequential Oligogenic Linkage Analysis 
Routines)55, with similar results from Merlin54, using multipoint IBD probabilities obtained 
from Merlin. LOD scores were computed with and without covariates (sex and average BMI 
Z-score). Multipoint LODs>2.0 was considered suggestive and LOD>3.7 was considered 
genome-wide significant15.
WFDR and SFDR methods
Let Pi be the p-value of an association test for SNP i, i =1,…,m. Converting p-values to q-
values56 controls the FDR. SNPs with q-values less than the FDR threshold value (e.g. γ = 
0.05) are declared significant. The expected proportion of false positives among all the 
positives is then controlled at level γ. Note that ranking SNPs by P-value or q-value are 
equivalent.
Let Zi be the linkage score of SNP i obtained from a GWL study. For the SFDR method, m 
SNPs are divided into K disjoint strata based on the prior linkage information57. Cconsider 
K = 2 and assign each SNP i to stratum 1 (the high priority group) or stratum 2 (the low 
priority group) according to whether the linkage score Zi exceeds a threshold C (we used 
C=3.3 corresponding to significant linkage15). Q-values are then calculated separately for 
each stratum of SNPs, achieving FDR control in each stratum (Sun et al., 2006). Ranks of 
the GWAS SNPs are determined by the q-values with the original association p-values used 
to break any q-value ties.
WFDR calculates a weighting factor Wi for each SNP i with weights subject to two 
constraints: Wi ≥ 0_ and W̄ = Σi Wi /m = 1. The weight Wi is proportional to the linkage 
signal Zi for SNP i (e.g.Wi exp(B · Zi) / ν, ν = Σi exp(B · Zi)/m,, and B=1) (Roeder et al., 
2006), and the FDR procedure is applied to the set of weight-adjusted p-values, Pi/Wi, i =1,
…,m. We use B=2 in the present analysis. The WFDR and SFDR were implemented in a 
perl program called SFDR, available at http://www.utstat.toronto.edu/sun/Software/SFDR/
index.html.
Phenotype variation attributable to association and to linkage
The proportion of variation due to each SNP was measured as the change in regression sums 
of squares vs. the smaller model with the SNP removed58. Using the genome-scan threshold 
of P=5 ×10-8 and minimum P=3.34 × 10-8 in the chromosome 11p13 region for GMS and 
CGS F508del/F508del patients, we estimate a 57.4% reduction in effect size compared to 
the nominal result. Using the joint analysis based on GMS, CGS F508del/F508del and TSS 
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F508del/F508del patients, the observed minimum P=8.28 × 10-8 results in ~ 28.0% 
reduction of the effect size. Using the rough parallel to explained variation in the trait, the 
estimated explained variation for 11p13 remains 1%-2%. For a linkage study of comparable 
size (n=500 sibling pairs), with a phenotype heritability of 0.5, the bias attributed to the 
winner’s curse varies from approximately 0.46 down to zero as the true (unmeasured) 
heritability attributable to the QTL increases16. While not possible to quantify the magnitude 
of this bias in this single study, these calculations provide an upper bound on the bias of 0.38 
to 0.46 and a lower bound of 0.04 to 0.12.
Estimation of changes in the CF lung phenotype upon FEV1 %predicted and airway flow
Using 973 TSS individuals, a hypothetical quantity of 0.2 was added to each individual’s 
lung phenotype, to correspond to the effect size observed for the significant association of 
SNPs near EHF/APIP. The average raw FEV1 (in liters) was then back-extrapolated8 and 
FEV1 percent predicted values were generated using the predictive equations59,60. Height 
and age adjustments used to calculate the original quantitative lung phenotype were 
preserved. The average increase (mean ± SD) in FEV1 percent predicted corresponding to a 
0.2-unit increase of our lung phenotype was 5.09% ± 1.90% [n = 841; Range: 0.00 – 
14.53%]. The corresponding average increase in raw FEV1 was 253.5 ± 85.9mL in adult 
subjects (>18 years) [n = 244; Range: 0.0 – 630.0mL].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Histograms of the Consortium lung phenotype for the three cystic fibrosis studies show 
similar average phenotypes. The phenotype mean is above zero due to a lower bound placed 
by the survival correction, as well as cohort effects of improving lung function. (a) The two 
designs using unrelated individuals. All of the patients in the Genetic Modifier Study (GMS) 
are F508del/F508del at CFTR. These patients were oversampled at extremes of an initial 
entry phenotype, in order to improve power, and the original severe/mild designations are 
colored separately. In contrast, the Canadian Consortium for Genetic Studies (CGS) is 
population based, representing a range of pancreatic insufficient CFTR genotypes. (b) 
Patients enrolled in the family-based Twin and Sibling Study (TSS) show a similar 
distribution of the Consortium lung phenotype as the population-based CGS.
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Genome-wide Manhattan plots for the cystic fibrosis Consortium lung function phenotype, 
combining the association evidence from GMS and CGS samples across 570,725 SNPs. The 
black dashed line represents the Bonferroni threshold for genome-wide α=0.05, while the 
green dashed line is the suggestive association threshold, expected once per genome scan. 
SNPs are plotted in Mb relative to their position on each chromosome (alternating blue and 
black) (a) Results from GMS (n=1137, all of whom are F508del/F508del) combined with all 
of the CGS patients (n=1357). Seven regions reach suggestive significance. (b) Results from 
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the combined evidence of GMS (n=1137) and the CGS F508del/F508del (n=841). A region 
on chromosome 11p13 reaches genome-wide significance (P=3.34 × 10-8).
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A plot of the association evidence in GMS and CGS F508del/F508del in the chromosome 
11p13 EHF/APIP region (NCBI build 36, LocusZoom viewer). Colors represent HapMap 
CEU linkage disequilibrium r2 with the most significant SNP, rs12793173 (P=3.34 × 10-8). 
The secondary peak at rs286873 has relatively low r2 with the primary peak.
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Genome-wide linkage scan for the Consortium lung phenotype of 486 sibling pairs in the 
family-based TSS, adjusted for sex. A QTL with a genome-wide significant LOD=5.03 was 
found on 20q13.2. LOD scores with SNPs used in the linkage panel are plotted in cM 
relative to their position on each chromosome (alternating blue and black).
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Regional analysis of the QTL on chromosome 20q13.2 (a) A detailed chromosome 20 
linkage plot for the Consortium lung phenotype in the TSS study, with covariates sex 
(essentially the same result as for no covariates) and with covariates sex and BMI. (b) 
Association evidence from the GMS and CGS F508del/F508del patients, in the 1-LOD 
support interval provided by TSS. A region centromeric to CBLN4 and MC3R on 20q13.2 
shows suggestive evidence of association, with the greatest evidence at rs6024460 (P=1.34 
× 10-4).
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Table 1
Characteristics of patients enrolled by the three studies comprising the North American CF Gene Modifier 
Consortium
Genetic Modifier Study (GMS) Canadian Consortium for 
Genetic Studies (CGS)
Twins & Sibs Study (TSS)
Lead Institution(s) Univ. of North Carolina/Case Western Hosp. Sick Children Johns Hopkins
 Design Extremes-of-Phenotype Unrelated Population-Based Unrelated Family-Based
 Type of Evidence Association Association Linkage and association
Number of patients
1,137
1,357 973 a (486 sibling pairs)
Severe (n = 406) Mild (n = 731)
Age
 Mean ± SD (yrs) 15.2 ± 4.6 27.5 ± 9.8 18.5 ± 9.5 15.5 ± 7.8
 Range (yrs) 8-25 15-56 6-49 6-55
Male n (%) 194 (47.8%) 405 (55.4%) 734 (54.1%) 521 (53.5)
Caucasian n (%)b 1,137 (100.0%) 1,180 (87.0%) 898 (92.3%)
F508del/F508del n (%) 1,137 (100.0%) 841 (62.0%) 557 (57.2%)
Pancreatic Exocrine 
Insufficient n (%)
1,137 (100.0%) 1,357 (100.0%) 973 (100.0%)
a
420 two-sib families, 20 three-sib families, 1 four-sib family and 69 singletons.
b
Based on self-identified ancestry and principal components analysis.
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